The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients ...

Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing ...

In a new study, pulse oximeters underestimated arterial oxygen saturation among patients in the ICU, and the ability of the ...

CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...

Among patients with severe aortic stenosis at low surgical risk, transcatheter aortic valve replacement and surgery conferred ...

The American Heart Association (AHA) is thrilled to announce a new collaboration between the New England Journal of Medicine ( NEJM) and the AHA’s flagship journal Circulation. Research authors have ...

Artificial intelligence (AI) could help sonographers identify any abnormalities at the 20-week pregnancy screening scan almost twice as quickly, without reducing the accuracy or reliability of ...

Researchers have identified in a new study that oral infigratinib, an FGFR1-3 selective tyrosine kinase inhibitor, improves ...

The FDA approved cabozantinib for previously treated, unresectable, locally advanced or metastatic, well-differentiated ...

Society / The New England Journal of Medicine has finally broken its silence on Gaza, only to obscure the truth of an ...

Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients with ...

Georgina V. Long, MD, MSc, discussed the long-term follow-up data for the combination of adjuvant dabrafenib and trametinib ...